CrownBio expands immuno-oncology offerings

By Melissa Fassbender contact

- Last updated on GMT

The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)
The additions come in response to a growing demand for immuno-oncology services (Image: iStock/royaltystockphoto)

Related tags: Flow cytometry, Medicine

Crown Bioscience has expanded its immuno-oncology platform at its facilities in Europe, the US, and Asia to include immunophenotyping analysis.

The expanded offerings include a collection of validated models and services for in vivo pharmacodynamic and efficacy studies, including multi-color flow cytometry, immunohistochemistry, and multiplex ELISA.

According to Jean Pierre Wery, President of Crown Bioscience, the additions come in response to a growing demand for immuno-oncology services - a market which is expected to see annual revenues of $25bn to $40bn by 2020, according to a report by Tufts​.

In particular, single cell-based FACS analysis has become a standard and essential tool to investigate the impact of Immuno-Oncology therapy in both murine and humanized systems in the preclinical setting​,” said Henry Li, VP of Translational Oncology at Crown Bioscience.

The ability to gate different sub-populations of T lymphocytes and myeloid compartment provides a rapid way for our clients to understand the impact of both single and combination therapies to significantly extend the reach of potential therapeutic effect across a larger population of patients​.”.

The company’s collection of syngeneic models, as well as its MiXeno™, MuPrime™, HuGEMM™ and humanized PDX platforms, can all be profiled using the immunophenotyping capacities for both pretreatment baseline and post treatment pharmacodynamic readouts.

The announcement follows CrownBio’s launch of its high throughput-screening platform, HuScreen in May. As Outsourcing-Pharma.com previously reported​, the platform seeks to improve preclinical studies using patient-derived xenograft (PDX) models.

Related topics: Bio Developments, Bio-Outsourcing

Related news

Related products

show more

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars